ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target

$16.73
-0.26 (-1.53%)
(As of 12:09 PM ET)

ACADIA Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 15 Analyst Ratings

Analysts' Consensus Price Target

$35.82
114.13% Upside
High Forecast$95.00
Average Forecast$35.82
Low Forecast$25.00
TypeCurrent Forecast
4/24/23 to 4/23/24
1 Month Ago
3/25/23 to 3/24/24
3 Months Ago
1/24/23 to 1/24/24
1 Year Ago
4/24/22 to 4/24/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
9 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$35.82$36.35$36.06$21.53
Predicted Upside114.13% Upside51.56% Upside40.80% Upside18.16% Upside
Get ACADIA Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.

ACAD Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ACAD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ACADIA Pharmaceuticals Stock vs. The Competition

TypeACADIA PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.68
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside110.85% Upside1,011.18% Upside11.07% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/10/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$37.00+110.35%
4/9/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$32.00+79.78%
3/25/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$29.00 ➝ $25.00+40.53%
3/13/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$40.00 ➝ $30.00+60.26%
3/12/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$39.00 ➝ $25.00+3.61%
2/28/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$33.00+38.71%
2/28/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$36.00 ➝ $35.00+49.57%
2/7/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Outperform ➝ Market Outperform$42.00+66.67%
2/5/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Perform ➝ Market Perform$25.00-0.79%
1/30/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$40.00+45.24%
12/18/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$25.00 ➝ $27.00-5.53%
12/13/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$38.00+79.50%
12/12/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy ➝ Buy$25.00+18.54%
10/17/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$33.00+38.77%
8/3/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$39.00 ➝ $38.00+36.01%
6/15/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$26.00 ➝ $29.00+20.13%
4/28/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$93.00 ➝ $95.00+363.41%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 12:27 PM ET.

ACAD Price Target - Frequently Asked Questions

What is ACADIA Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 15 analysts in the last year, the consensus rating for ACADIA Pharmaceuticals stock is Moderate Buy based on the current 3 hold ratings and 12 buy ratings for ACAD. The average twelve-month price prediction for ACADIA Pharmaceuticals is $35.82 with a high price target of $95.00 and a low price target of $25.00. Learn more on ACAD's analyst rating history.

Do Wall Street analysts like ACADIA Pharmaceuticals more than its competitors?

Analysts like ACADIA Pharmaceuticals more than other Medical companies. The consensus rating score for ACADIA Pharmaceuticals is 2.80 while the average consensus rating score for medical companies is 2.68. Learn more on how ACAD compares to other companies.

Is ACADIA Pharmaceuticals being upgraded or downgraded by Wall Street analysts?

Over the previous 90 days, ACADIA Pharmaceuticals's stock had 1 upgrade and 1 downgrade by analysts.

Does ACADIA Pharmaceuticals's stock price have much upside?

According to analysts, ACADIA Pharmaceuticals's stock has a predicted upside of 56.59% based on their 12-month stock forecasts.

What analysts cover ACADIA Pharmaceuticals?

Stock Ratings Reports and Tools

This page (NASDAQ:ACAD) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners